UnitedHealth Group

UnitedHealth Group (NYSE: UNH) Incorporated is a diversified healthcare company operating through its UnitedHealthcare insurance division and Optum health services platform. The company delivers patient-centered care, pharmacy services, and data-driven healthcare solutions, aiming to improve care quality, efficiency, and accessibility across individuals, providers, and broader healthcare systems.

FY25 Performance Review: Scale, Pressures, and Strategic Reset

• Revenue Expansion Amid Strong Market Positioning: During FY25, UnitedHealth Group reported consolidated revenues of USD 447.6 billion, reflecting a robust 12% year-over-year increase, supported by broad-based growth across both UnitedHealthcare and Optum segments. The expansion was driven by higher member volumes, pricing adjustments aligned with medical cost trends, and continued demand for integrated healthcare services.
• Profitability Compression Due to One-Time Charges and Cost Pressures: Despite strong revenue growth, operating earnings declined significantly to USD 19.0 billion in FY25, compared to materially higher levels in the prior year, primarily due to a USD 2.8 billion charge linked to cyberattack-related costs, restructuring initiatives, and portfolio adjustments. These factors, combined with elevated medical costs, compressed profitability and reduced margins during the year.
• Elevated Medical Cost Trends Impacting Margins: The company experienced notable pressure from rising medical care costs, with the adjusted medical care ratio increasing to 88.9% in FY25 from 85.5% in FY24. This deterioration was driven by Medicare funding reductions, regulatory changes under the Inflation Reduction Act, and higher utilization trends, which collectively weighed on underwriting margins and operating performance.

Segmental Performance Dynamics

• UnitedHealthcare: Revenue Strength with Margin Compression: UnitedHealthcare delivered strong top-line performance, with FY25 revenues rising 16% year-over-year to USD 344.9 billion, supported by growth in Medicare and Medicaid offerings. However, operating earnings declined to USD 9.4 billion from USD 15.6 billion in FY24, with margins contracting to 2.7%, reflecting regulatory headwinds and elevated healthcare utilization costs.
• Optum: Mixed Performance Across Business Segments: Optum reported revenue growth of 7% to USD 270.6 billion in FY25, supported by expansion in pharmacy services and analytics capabilities. However, segment profitability weakened, with total operating earnings declining to USD 9.5 billion, impacted by losses in Optum Health, investment spending in Optum Insight, and restructuring activities.
• Optum Health Weakness Versus Optum Rx Strength: Within Optum, Optum Health revenues declined 3% year-over-year to USD 102.0 billion, with operating losses reported due to reimbursement pressures and higher care costs. In contrast, Optum Rx delivered strong performance, with revenues increasing 16% to USD 154.7 billion and operating earnings rising to USD 7.2 billion, driven by higher prescription volumes and operational efficiencies.

Operational and Strategic Developments

• Strategic Realignment and Operational Reset: During FY25, the company undertook significant strategic actions to improve long-term performance, including portfolio optimization, pricing recalibration, leadership restructuring within Optum, and enhanced operational transparency. These initiatives were aimed at addressing cost inflation, strengthening execution discipline, and positioning the company for sustainable growth in FY26 and beyond.

Key Risks:

• Elevated Medical Cost Trends: Rising healthcare utilization and cost inflation could continue to pressure margins, particularly within risk-based insurance and value-based care models.
• Regulatory and Policy Changes: Dependence on Medicare and Medicaid exposes the company to funding reductions, reimbursement changes, and evolving healthcare regulations.
• Operational and Cybersecurity Risks: Exposure to cyber incidents and large-scale operational disruptions may lead to financial losses, reputational damage, and higher compliance costs.
• Execution Risks in Optum Transformation: Ongoing restructuring, pricing recalibration, and integration across Optum businesses may impact near-term profitability and operational stability.

Technical Observation (on the daily chart):

• The stock exhibits a broad downtrend from prior highs (USD 606.36) followed by a prolonged sideways consolidation phase, indicating loss of strong bullish momentum.
• Price action is currently trading below the 50-day moving average (~USD 284) but near the 20-day moving average (~USD 276), suggesting short-term stabilization but no clear breakout.
• The range-bound movement between ~USD 260 and ~USD 300 reflects indecision, with neither buyers nor sellers establishing dominance.
• RSI at ~61 indicates mild bullish momentum, but not overbought, implying potential for gradual upside if supported by volume.
• Volume remains relatively moderate, with no strong accumulation signals, reinforcing the consolidation outlook..

During FY25, the company undertook significant strategic actions to improve long-term performance, including portfolio optimization, pricing recalibration, leadership restructuring within Optum, and enhanced operational transparency. These initiatives were aimed at addressing cost inflation, strengthening execution discipline, and positioning the company for sustainable growth in FY26 and beyond.

Given the diversified healthcare platform with strong scale and integrated capabilities, supporting long-term growth resilience despite near-term cost pressures. Henceforth, a ‘Buy’ rating has been given to UnitedHealth Group (NYSE: UNH) at the closing market price of USD 281.36 as of April 06,2026. 

Individuals can evaluate the stock based on the support and resistance levels provided in the report in case of keen interest taking into consideration the risk-reward scenario. 

Markets are trading in a highly volatile zone currently due to certain macro-economic issues and prevailing geopolitical tensions. Therefore, it is prudent to follow a cautious approach while investing.

Related Risk: This report may be looked at from a high-risk perspective and a recommendation is provided for a short duration. This report is solely based on technical parameters, and the fundamental performance of the stocks has not been considered in the decision-making process. Other factors which could impact the stock prices include market risks, regulatory risks, interest rates risks, currency risks, social and political instability risks etc. 

Note 1: Past performance is not a reliable indicator of future performance.

Note 2: The reference date for all price data, currency, technical indicators, support, and resistance level is April 06,2026. The reference data in this report has been partly sourced from REFINITIV.

Note 3: Investment decisions should be made depending on an individual's appetite for upside potential, risks, holding duration, and any previous holdings. An 'Exit' from the stock can be considered if the Target Price mentioned as per the Valuation and or the technical levels provided has been achieved and is subject to the factors discussed above.

Note 4: Target Price refers to a price level that the stock is expected to reach as per the relative valuation method and or technical analysis taking into consideration both short-term and long-term scenarios.

Note 5: ‘Kalkine reports are prepared based on the stock prices captured either from the New York Stock Exchange (NYSE), NASDAQ Capital Markets (NASDAQ), and or REFINITIV. Typically, all sources (NYSE, NASDAQ, or REFINITIV) may reflect stock prices with a delay which could be a lag of 15-20 minutes. There can be no assurance that future results or events will be consistent with the information provided in the report. The information is subject to change without any prior notice.